000908213 001__ 908213
000908213 005__ 20220923174128.0
000908213 0247_ $$2doi$$a10.1177/0271678X19851018
000908213 0247_ $$2ISSN$$a0271-678X
000908213 0247_ $$2ISSN$$a1559-7016
000908213 0247_ $$2pmid$$a31265793
000908213 0247_ $$2WOS$$aWOS:000473954100004
000908213 037__ $$aFZJ-2022-02464
000908213 082__ $$a610
000908213 1001_ $$0P:(DE-Juel1)171754$$aRégio Brambilla, Claudia$$b0$$ufzj
000908213 1112_ $$aBrainPET 2019$$cYokohama$$d2019-07-04 - 2019-07-07$$wJapan
000908213 245__ $$aSignificant decreases in [11C]ABP688 binding after a mismatch negativity paradigm - Brain PET Poster Sessions PP01-M01 to PP02-N07
000908213 260__ $$c2019
000908213 3367_ $$0PUB:(DE-HGF)1$$2PUB:(DE-HGF)$$aAbstract$$babstract$$mabstract$$s1655816978_16933
000908213 3367_ $$033$$2EndNote$$aConference Paper
000908213 3367_ $$2BibTeX$$aINPROCEEDINGS
000908213 3367_ $$2DRIVER$$aconferenceObject
000908213 3367_ $$2DataCite$$aOutput Types/Conference Abstract
000908213 3367_ $$2ORCID$$aOTHER
000908213 520__ $$aThe present work explores a novel estimation method based on a Markov-Chain Monte-Carlo (MCMC) sampling in a Bayesian context. This new methodology allows the integration of prior knowledge on parameters that constrain the available solutions, which alleviates the identifia-bility problem. It also quantifies the uncertainty of the parameters and does not rely on a set of chosen basis functions as the original method does. Methods: The proposed method relies on a stochastic approach which consists in assessing the whole posterior distribution of the parameters, i.e. estimating the probability of the parameters given the measurements. According to Bayes rule, the posterior distribution is proportional to the product of the likelihood and the prior. The likelihood, which corresponds to the noise model, is here considered normally distributed with the variance at each time point scaled by the decay factor and the frame duration. The prior is a uniform distribution in an interval of plausible values for each parameter. The posterior distribution is then approximated with MCMC using a hybrid Metropolis-within-Gibbs sampler, 2 where the step size of each chain is adjusted to ensure an optimal mixing behavior. For performance evaluation of the method, realistic dynamic whole brain PET data of a 90-minute bolus-infusion [ 11 C]raclopride protocol have been simulated using PET-SORTEO 3 for 21 structurally different subjects. Time activity curves (TAC) used as input for simulations included a dopamine release at 40 minutes in specific regions (Caudate, Accumbens and Putamen), with four different magnitudes of TAC decrease (0, 5, 10 and 25% of the basal TAC, respectively named placebo, stim05, stim10, stim25). To fit the lp-ntPET model on the reconstructed TACs, 5000 samples have been drawn with the proposed MCMC sampler. This few amount of samples has been shown to be sufficient considering the early convergence of the chains. Results: The maximum a-posteriori (MAP) estimates of each parameter have been derived from the marginal distributions for each condition and each region over the 21 subjects. Figure 1 shows the Displacement Ratio 4 calculated from these estimates. Results show that the obtained DRs allow to better distinguish the four simulated experimental conditions than the original method, even on small noisy regions such as the Accumbens. Conclusions: The early results show promising potential for estimating the parameters of the lp-ntPET model in a Bayesian framework. Current work explores the resolution of lp-ntPET at a voxel level, by integrating prior knowledge on spatial regularity with or without the use of anatomical MRI. Abstract Objectives: The glutamatergic receptor (mGluR5) is under investigation in clinical neurology and of great interest in several lines of research [1-3]. We assessed the feasibility of using [ 11 C]ABP688 to evaluate changes in glutamate levels through the Mismatch Negativity (MMN) auditory paradigm 4 as a part of a multimodal study. 5 Methods: Five healthy, male, non-smoking subjects were scanned with a Siemens 3 T MR-BrainPET insert. We analyzed the effect of MMN comparing the changes in non-displaceable binding potential (BP ND) prior, during and after the MMN with a bolus/infusion protocol during the tracer steady-state (50% of the total injected activity (446.4 AE 106.0 MBq) was infused during 65 minutes after bolus injection). Image reconstruction was performed with 3D-OP-OSEM (2 subsets, 32 iterations), isotropic Abstracts 545 voxel ¼ 1.25 mm 3 , 153 slices, matrix of 256 Â 256 pixels, and a frame scheme of 2 minutes. PET frames were synchronized with the different acquisition moments. The images were corrected for attenuation [6], random and scattered coincidences, and dead time. Post processing with a 2.5 mm 3D Gaussian filter and motion correction were performed. Anatomical images were acquired with T1 MPRAGE sequence (TR ¼ 2250 ms, TE ¼ 3.03 ms, 176 slices, 1 mm slice thickness). The MMN paradigm consisted of changes in tone duration and was presented in alternating sequences. The deviant positions were pseudo-randomized and a silent video was presented to the subject. PMOD software was used to define the volumes of interest (VOIs) with T1 images serving as the anatomical reference. All images were finally processed in the PET subject's space, and the Hammers atlas 7 was used for activity concentration analysis. The maximum probability operation was applied to generate the VOIs in the grey matter cortex (GM). Furthermore, functional network regions, 8 GM corrected, were also applied. Cerebellum GM was chosen as the reference region. Statistical analysis was performed using repeated ANOVA with inter-subject corrections. 9 Results: There was a significant ÁBP ND between conditions. On average, the reductions across all regions and subjects were of À11.46 AE 3.39%, F (2,6) ¼ 7.471; P < 0.05 in anatomical [FIGURE 1 (a)] and À10.37 AE 4.33%, F (2,8) ¼ 6.674; P < 0.05 in functional VOIs [FIGURE 1 (b)].
000908213 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x0
000908213 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
000908213 7001_ $$0P:(DE-Juel1)138474$$aMatusch, Andreas$$b1$$ufzj
000908213 7001_ $$0P:(DE-Juel1)144215$$aMauler, Jörg$$b2$$ufzj
000908213 7001_ $$0P:(DE-Juel1)164396$$aRajkumar, Ravichandran$$b3$$ufzj
000908213 7001_ $$0P:(DE-Juel1)131788$$aRota Kops, Elena$$b4$$ufzj
000908213 7001_ $$0P:(DE-Juel1)131752$$aBoers, Frank$$b5$$ufzj
000908213 7001_ $$0P:(DE-Juel1)131768$$aHerzog, Hans$$b6$$ufzj
000908213 7001_ $$0P:(DE-Juel1)131794$$aShah, N. J.$$b7$$ufzj
000908213 7001_ $$0P:(DE-Juel1)164254$$aLerche, Christoph$$b8$$ufzj
000908213 7001_ $$0P:(DE-Juel1)131781$$aNeuner, Irene$$b9$$ufzj
000908213 773__ $$0PERI:(DE-600)2039456-1$$a10.1177/0271678X19851018$$gVol. 39, no. 1_suppl, p. 524 - 608$$x1559-7016$$y2019
000908213 909CO $$ooai:juser.fz-juelich.de:908213$$pVDB
000908213 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)171754$$aForschungszentrum Jülich$$b0$$kFZJ
000908213 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)138474$$aForschungszentrum Jülich$$b1$$kFZJ
000908213 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)144215$$aForschungszentrum Jülich$$b2$$kFZJ
000908213 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)164396$$aForschungszentrum Jülich$$b3$$kFZJ
000908213 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131788$$aForschungszentrum Jülich$$b4$$kFZJ
000908213 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131752$$aForschungszentrum Jülich$$b5$$kFZJ
000908213 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131768$$aForschungszentrum Jülich$$b6$$kFZJ
000908213 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131794$$aForschungszentrum Jülich$$b7$$kFZJ
000908213 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)164254$$aForschungszentrum Jülich$$b8$$kFZJ
000908213 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131781$$aForschungszentrum Jülich$$b9$$kFZJ
000908213 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000908213 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz$$d2021-02-04$$wger
000908213 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-02-04
000908213 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-02-04
000908213 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-02-04
000908213 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-02-04
000908213 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-02-04
000908213 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-04
000908213 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-02-04
000908213 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-04
000908213 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-04
000908213 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-02-04
000908213 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CEREBR BLOOD F MET : 2019$$d2021-02-04
000908213 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-02-04
000908213 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-02-04
000908213 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ CEREBR BLOOD F MET : 2019$$d2021-02-04
000908213 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x0
000908213 9201_ $$0I:(DE-Juel1)INM-11-20170113$$kINM-11$$lJara-Institut Quantum Information$$x1
000908213 9201_ $$0I:(DE-Juel1)VDB1046$$kJARA-BRAIN$$lJülich-Aachen Research Alliance - Translational Brain Medicine$$x2
000908213 980__ $$aabstract
000908213 980__ $$aVDB
000908213 980__ $$aI:(DE-Juel1)INM-4-20090406
000908213 980__ $$aI:(DE-Juel1)INM-11-20170113
000908213 980__ $$aI:(DE-Juel1)VDB1046
000908213 980__ $$aUNRESTRICTED